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Abstract
Purpose Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared and disturbing adverse events of cancer
treatment associated with decreased adherence to effective chemotherapy regimens. For high-risk soft tissue sarcoma patients,
receiving multiple-day chemotherapy (MD-CT), antiemetic guidelines recommend a combination of an NK1 receptor antagonist
(NK1-RA), a 5-HT3 receptor antagonist (5HT3-RA), and dexamethasone on each day of the antineoplastic treatment. NEPA is the
first oral fixed-dose combination of a highly selective NK1-RA, netupitant, and second-generation 5HT3-RA, palonosetron. So
far, no data has been published in literature about the efficacy of a single dose of NEPA in MD-CT.
Methods We performed a prospective, non-comparative study to assess the efficacy of one shot of NEPA plus dexamethasone in
sarcoma patients receiving MD-CT. The primary efficacy endpoint was a complete response (CR: no emesis, no rescue medi-
cation) during the overall phase (0–120 h) in cycle 1. The main secondary endpoints were CR during the overall phase of cycles 2
and 3.
Results The primary endpoint was reached in 88.9% of patients. Cycles 2 and 3 overall CR rates were 88.9% and 82.4%,
respectively. The antiemetic regimen was well tolerated.
Conclusions This pilot study showed the benefit of one shot of NEPA to prevent CINV in sarcoma patients receiving MD-
chemotherapy.
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Introduction
Chemotherapy is still the mainstay treatment of several solid
tumors, and chemotherapy side effects (CSEs) are often re-
sponsible for quality of life (QoL) deterioration impairing
patients’ ability to manage daily activities [1]. In a recent
study, Lorusso et al. highlighted that chemotherapy-induced
nausea and vomiting (CINV) is one of the most feared adverse
events before starting chemotherapy and is still the most com-
monly experienced during treatment. Prophylaxis for CINV is
still an unmet medical need in cancer treatment, and antiemet-
ic strategies should be improved in the future [2]. CINV risk
factors are well defined for both chemotherapy regimens and
patients: type, dose and chemotherapy schedule, female gen-
der, young age (< 55 years), non-users of alcohol, previous
nausea and vomiting due to cancer treatment or pregnancy,
anxiety, and motion sickness [3].
International guidelines provide recommendations for an-
tiemetic prophylaxis according to the emetogenic potential of
chemotherapy [4–6]. High and moderate emetogenic chemo-
therapies need a multi-drug approach with a combination of 5-
HT3 and NK1 receptor antagonists. Chemotherapy regimens
for soft tissue sarcoma patients are often delivered for multiple
days, often resulting in poor management of CINV due to the
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daily infusion of chemotherapy. Antiemetic guidelines in pa-
tients receiving multiple-day chemotherapy (MD-CT) recom-
mend the use of antiemetic drugs before treatment that are
appropriate for the emetic risk of the antineoplastic agent ad-
ministered on each day of the antineoplastic treatment and for
2 days after completion of the antineoplastic regimen. In high-
risk patients receiving MD-CT, a three-drug combination of
an NK1 receptor antagonist (NK1-RA), a 5-HT3 receptor an-
tagonist (5HT3-RA), and dexamethasone should be consid-
ered. The efficacy of different antiemetic triplet regimens
has been evaluated in sarcoma patients receiving MD-CT:
aprepitant plus dexamethasone in combination with one shot
of palonosetron or multiple days of granisetron. No significant
differences have been detected between the two antiemetic
regimens, and CINV control has been considered insufficient,
with less than 50% of patients having been controlled [7]. The
combination of netupitant 300 mg plus palonosetron 0.50 mg
(NEPA) has recently been approved as a prophylactic anti-
emetic strategy for patients treated with chemotherapy.
Netupitant, the NK1-RA component of NEPA, is a new highly
selective NK1-RA that can saturate NK1 receptors up to 90%
and has a longer half-life (96 h) than aprepitant (9–13 h) [8].
The rationale for the combination of the two active principles
of NEPA is based on their unique and complementary action
on the NK1 receptor [8]. No data has been published in liter-
ature about the efficacy of a single dose of NEPA in MD-CT,
neither in the oncology nor in the hematology setting.
Therefore, we carried out a pilot study to assess the efficacy
of one shot of NEPA plus dexamethasone in sarcoma patients
receiving MD-CT.
Methods
This prospective, non-comparative study was conducted in the
Oncology Department of Palermo University, Italy. The study
was approved by the local ethics committee, and all patients
signed the informed consent form. Eligible patients were
18 years old or older, with a diagnosis of soft tissue tumors
and were scheduled to receive a MD-CT of epirubicin (EPI)
35mg/m2 days 1–3 and ifosfamide (IFO) 3000mg/m2 days 1–
3 every 21 days. Other eligibility criteria were ECOG 0–2,
adequate bone marrow function, hepatic and renal function,
and the willingness and ability of patients to complete a diary.
The main exclusion criteria were the presence of vomiting or
nausea before chemotherapy administration and hypersensi-
tivity to palonosetron or netupitant.
For antiemetic prophylaxis, all patients received a single
dose of NEPA on day 1 only and dexamethasone 12 mg on
days 1, 2, and 3. A dose escalation of dexamethasone was done,
4 mg/bid on days 4, 5, and 6 and 2 mg/bid on days 7, 8, and 9.
Metoclopramide has been prescribed as rescue medication.
Patients kept a self-assessed diary, from day 1 to day 7 to
assess nausea (Likert scale: none, mild/moderate, or severe)
and record episodes of vomiting. A 10-point visual analogue
scale was completed by patients at the end of the 7-day as-
sessment. In the morning of day 8, the patients returned their
diaries, and all the data entered were discussed with the
physician.
The primary endpoint of the study was to evaluate the
complete response (CR) rate during the first chemotherapy
cycle of EPI-IFO, during the overall phase (0–120 h after
chemotherapy administration). CR is defined as no vomiting
and no use of rescue medication. Other endpoints were CR
during the acute (0–24 h) and delayed (25–120 h) phase, no
vomiting and no nausea during the acute, delayed, and overall
phase of the first and subsequent cycles (maximum 3 cycles).
Treatment safety was evaluated during all chemotherapy
cycles, and all adverse events were recorded and graded ac-
cording to the common terminology criteria for adverse events
(CTCAE) described by the National Cancer Institute, version
4.0. (http://ctep.cancer.gov/forms/CTCAEv4.pdf).
Demographic data and patient characteristics were exam-
ined. The percentage of patients with CR and no vomiting or
nausea for the acute, delayed, and overall period was
calculated.
Table 1 Clinically relevant cytochrome interactions of NK1-RA
Cytochrome Netupitant [15] Aprepitant [12–19] Rolapitant [14]
CYP3A4 inhibition Dex, Ketoconazole Dex, CTX† No
CYP3A4 inducer Rifampicin CTX‡ No
CYP2C9 inducer No Warfarin, oral contraception No
CYP2D6 inhibition No No Drugs§
P-gP No No CTX¶
†Cyclophosphamide, bosutinib, cabazitaxel
‡ Ifosfamide, etoposide, vinorelbine, docetaxel, paclitaxel
§ Anti-arrhythmics, anti-depressants, antipsychotics, beta-blockers, analgesic
¶ Irinotecan, doxorubicin, methotrexate, bendamustine, rosuvastatin
CTX, chemotherapy; Dex, dexamethasone
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Results
Between January 2017 and June 2017, 18 patients affected by
sarcoma were enrolled. Fifty percent were male; the median
age was 53 (range 25–80), and patients received chemothera-
py for metastatic (8/18), neoadjuvant adjuvant (8/18), or ad-
juvant (2/18) intent. Seventeen patients completed the three
planned EPI-IFO cycles, while one patient did not undergo the
third cycle of treatment, due to disease progression. Four pa-
tients had received chemotherapy treatment previously, while
14 (77.8%) patients were naïve. Among the pre-treated pa-
tients, one patient received chemotherapy for Hodgkin
Lymphoma in 2001, one patient for breast cancer in 2010,
and 2 patients received chemotherapy for sarcoma, but they
did not experience nausea and vomiting during the treatment.
The primary endpoint was 88.9% of CR during the overall
phase. The no vomiting rate and CR rate are identical. None of
the patients required rescue medication at home during the
7 days of assessment. Figures 1 and 2 report the results of
CR-no vomiting and no nausea, respectively. All patients were
compliant to dexamethasone during the delayed phase.
No grade 3 or 4 toxicity was detected during the entire
study period. Patients experienced the following grades 1
and 2 adverse events: headache 16.6% (3/18), constipation
38.8% (7/18), hiccups 22% (4/18), anorexia 5.5% (17/18),
insomnia 27.7% (5/18), and heartburn 22.2% (4/18).
No neurotoxicity was detected in our patients.
Discussion
Antiemetic guidelines suggest a multi-therapy approach with
a combination of 5-HT3 and NK1 receptor antagonists for
patients receiving MD-CT [4–6]. It is well known that
CINV control could be improved by following antiemetic
guidelines. However, published studies have shown that it is
often suboptimal [9, 10]. A multi-therapy approach to manage
nausea and vomiting during all 5 days of the scheme could
make patient adherence more difficult, because it requires self-
administration of the medication at home. A simply guideline-
based antiemetic prophylaxis is warranted in oncology pa-
tients to enhance adherence and, therefore, efficacy [11], and
NEPA appears to be an advancement, particularly in the set-
ting of MD-CT [7].
To our knowledge, this is the first study evaluating the
efficacy and safety of one shot antiemetic drug of NEPA plus
dexamethasone to prevent CINV prophylaxis in the MD-CT.
In our study design, we assessed whether a single dose of
NEPA could cover the whole 5-day risk period of CINV
(3 days of chemotherapy plus 2 days after).
A single dose of NEPA plus dexamethasone covers all
7 days after starting chemotherapy both for vomiting and nau-
sea, reaching a high level of control during the entire study
period (acute, delayed, and overall) and for all three cycles.
Our efficacy results are higher, for both nausea and vomiting
control, with respect to previous reports combining NK1-RA
and 5HT3-RA [7]. Kimura and collaborators assessed the ef-
ficacy of aprepitant plus granisetron or palonosetron and this
three-drug combination was not sufficient to control CINV in
sarcoma patients receiving MD-CT. This study also demon-
strated that consecutive-day granisetron was not inferior to
single-shot palonosetron for treating CINV.
The safety profile of NEPA in our study is of particular
interest, because it is well known that NK1-RA interacts with
cytochrome: netupitant is an inhibitor of the CPY3A4, and
aprepitant and fosaprepitant are both inhibitors and inducers
of CPY3A4, while rolapitant is an inhibitor of CPY2D6 and it
interacts with PgP (see Table 1) [12–15]. In our study, the
safety profile of NEPAwith respect to possible clinical inter-
action is confirmed [16–18]. Additionally, in our patients, we
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did not detect, as expected [19], an increase in ifosfamide
neurotoxicity. This adverse event is reported for aprepitant/
fosaprepitant, since it is a CYP3A4 inducer.
In the setting of MD-CT, the choice of one-shot NEPA
schedule would allow the simplification of therapy by de-
creasing the number of individual dose units to be taken by
the patient, simplifying therapy, and improving patient com-
pliance. The correct timing and administered dose of the drugs
should be considered in order to optimize the prophylactic
treatment [20].
The limitation of our study is the small sample of patients, but
sarcoma tumor is a rare disease. Our study results should be
confirmed in future studies. Moreover, further studies are needed
to assess whether NEPA could allow a dexamethasone sparing
approach for antiemetic prophylaxis due to its long half-life and
to the synergy of the two active drugs on the NK1-receptor [21].
Conclusions
Nowadays, although advances have been made in the man-
agement of nausea and vomiting, CINV remains one of the
most dreaded side effects of chemotherapy. When poorly con-
trolled, CINV can negatively impact the patient’s ability to
tolerate chemotherapy and can affect their quality of life.
It has been demonstrated that adherence to antiemetic
guidelines guarantees more effective control of CINV. In our
study, one-shot NEPA administration appears to be an ad-
vance, particularly with its simplicity of administering
guideline-based antiemetic prophylaxis.
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